Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

This trial uses early treatment response — measured 14 days into therapy — to personalise and adapt subsequent treatment in older or frail patients with newly diagnosed acute myeloid leukaemia (AML) who cannot tolerate intensive chemotherapy. By checking how much leukaemia remains (called MRD — measurable residual disease) at day 14, doctors can decide whether to escalate or change treatment to improve outcomes. **You may be eligible if...** - You are 75 or older, OR you are 18–74 with health conditions that make intensive chemotherapy too risky (such as heart failure, poor lung function, reduced kidney function, or other serious comorbidities) - You have been newly diagnosed with AML - Your liver and kidney function meet minimum thresholds - You are expected to live at least 4 weeks **You may NOT be eligible if...** - You have AML in the brain or spinal fluid - You have received any prior AML treatment (other than hydroxyurea to control white cell count) - You have another active cancer - You have HIV, active hepatitis B, or active hepatitis C Talk to your doctor to see if this trial is right for you.